Intangible Assets, Net - ProstaGene (Details) - USD ($) shares in Millions, $ in Millions |
1 Months Ended | 3 Months Ended | |
|---|---|---|---|
May 19, 2022 |
Mar. 31, 2021 |
Feb. 28, 2021 |
|
| Intangible Assets, net | |||
| Shares subject to arbitration | 3.1 | ||
| Intangible asset impairment charge | $ 10.0 | ||
| Impairment charge, gross | 12.2 | ||
| Impairment charge, reversal of accumulated amortization | $ 2.2 | ||
| Non cash charge | $ 0.8 |
| X | ||||||||||
- Definition The number of shares subject to arbitration in connection with acquisition of intangible asset. No definition available.
|
| X | ||||||||||
- Definition The portion of the intangible asset impairment expense recognized during the period that is attributable to the original gross value/cost of the asset. No definition available.
|
| X | ||||||||||
- Definition The portion of the intangible asset impairment expense recognized during the period that reflects reversal of accumulated amortization through impairment date. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. No definition available.
|